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Lymph node metastasis (LNM) in many solid cancers is a well-known prognostic factor; however, it has been
debated whether regional LNM simply reflects tumor aggressiveness or is a source for further tumor
dissemination. Similarly, the metastatic process in head and neck cancer (HNC) has not been fully evaluated.
Thus, we aimed to investigate the relative significance of LNM in metastatic cascade of HNC using functional
imaging of HNC patients and molecular imaging in in vivo models. First, we analyzed 18Fluorodeoxyglucose
positron emission tomography (PET) parameters of 117 patients with oral cancer. The primary tumor and nodal
PET parameters were measured separately, and survival analyses were conducted on the basis of clinical and PET
variables to identify significant prognostic factors. In multivariate analyses, we found that only the metastatic node
PET values were significant. Next, we compared the relative frequency of lung metastasis in primary ear tumors
versus lymph node (LN) tumors, and we tested the rate of lung metastasis in another animal model, in which each
animal had both primary and LN tumors that were expressing different colors. As a result, LN tumors showed
higher frequencies of lung metastasis compared to orthotopic primary tumors. In color-matched comparisons, the
relative contribution to lung metastasis was higher in LN tumors than in primary tumors, although both primary
and LN tumors caused lung metastases. In summary, tumors growing in the LN microenvironment spread to
systemic sites more commonly than primary tumors in HNC, suggesting that the adequate management of LNM
can reduce further systemic metastasis.
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Lymph node metastasis (LNM) in many solid cancers including head
and neck cancer (HNC) is a well-known and clinically accepted
prognostic factor [1,2]. However, it has been debated whether LNM
reflects tumor aggressiveness or invasiveness or is a foothold for further
tumor dissemination [3]. The early concept of a metastatic cascade in
solid cancers was the sequential progress of tumors from the primary sites
to lymph nodes (LNs) and then systemically distant organs (Halstedian
theory) [4,5]. In contrast, the systemic theory of cancer metastasis
highlighted the view that cancer is a systemic disease, and cancer cells
disperse throughout the body at the very early phase of tumor formation
[6,7]. According to this theory, the status of LNM only provides
prognostic information; therefore, surgical removal of metastatic nodes
does not affect patient survival. However, many clinical observations of
breast [8], stomach [9], endometrial [10], and esophageal cancers [11]
have not fit well into these two categories, and a spectrum theory was
proposed explaining that tumor cells gain more metastatic capabilities as
the tumor progresses to regional LNs [3,12] (Figure S1). Halstedian
theory does not accept the direct dissemination of tumor from primary
tumor to systemic sites [5]; however, the spectrum theory describes
systemic tumor dissemination both from primary tumors and LNM but
supposes that tumor cells spread more to systemic sites from LNM,
which can be a major source of systemic disease [3].
InHNC, there have been no clear data, but similarly the active control
of regional as well as local diseases is recommended for better survival of
HNC patients [National Comprehensive Cancer Network (NCCN)
Clinical Practice Guideline in Oncology, Head and Neck Cancer,
Version 2.2013].Molecular and genetic characteristics of cancer cells can
be the main determinants of metastasis in HNC [13], and the active
dissemination to blood and lymphatic vessels in the primary tumor was
suggested [7]. However, the relative significance of the established LNM
in further cancer dissemination of HNC has never been studied fully.
Regional LNM is a major prognostic factor for HNC, because it
indicates aggressive tumor biology, as well as represents a source of
subsequent metastasis (as explained by the spectrum theory) [3,14].
In addition, the tumor biology and phenotype within the primary
site microenvironment can differ from those of the metastatic LNs
[15–17]. More importantly, tumor cells in different microenviron-
ments have been reported to respond differently to therapy [17–19].
Thus, increasing evidence indicates that to determine optimal
treatment and to better predict prognosis, evaluation of cancer
patients should be refined on the basis of the primary tumor and
metastatic microenvironment.
Despite this body of knowledge, the significance of LNM and LN
microenvironment has not been evaluated. Thus, the aims of this
study were to provide clinical and experimental evidence regarding
the role of established LNM in the metastatic cascade of HNC by
analyzing functional imaging in HNC patients and using molecular
imaging in in vivo models. Understanding metastasis progression of
HNC in tumor site–specific microenvironments can lead to
personalized treatments and refine the design of many clinical trials
enrolling patients with metastatic/recurrent HNC.Materials and Methods
Evaluation of 18F-FDGPET/CT Imaging inOral Cancer Patients
First, we evaluated the 18Fluorodeoxyglucose positron emission
tomography (18F-FDG PET)/computed tomography (CT) imagingin HNC patients. Our study population was limited to oral cavity
squamous cell carcinoma patients, because the standard treatment is
initial surgery and/or post-operative adjuvant treatment, which
enabled us to access pathologic information. Newly diagnosed oral
cavity cancer patients were prospectively enrolled in the study from
2006 to 2012. All participants provided written informed consent
before the study. The diagnosis of oral cavity squamous cell carcinoma
was confirmed by surgical pathology in all subjects. Patients with other
pathology types, uncontrolled diabetes, or high blood glucose level
(N200 mg/dl), secondary malignancies, or who failed to receive
definitive treatment for disease were excluded from the analyses (N =
20). Finally, 117 patients were included in this study. All patients
were subjected to curative resection of the primary tumor with neck
LN dissection (N = 71) or sentinel LN biopsy (N = 46). The
demographics and clinicopathologic characteristics of the patients
are summarized in Table S1. Whole-body 18F-FDG PET and
unenhanced CT images were acquired using integrated PET/CT
scanners according to the standard protocols (Discovery LS or
Discovery STE; GE Healthcare, Pittsburgh, PA).
Measurement of 18F-FDG PET Variables
18F-FDG PET measurements were performed using the Volume
Viewer software on the GE Advantage Workstation version 4.4 (GE
Healthcare). This software automatically determines the volume of
interest using an iso-contour thresholdmethod based on the standardized
uptake value (SUV). The volumes of interest were placed over the target
lesions within the primary sites as well as all suspicious metastatic LNs,
and the software subsequently measured the maximum SUV (SUVmax),
average SUV, and metabolic tumor volume (MTV). The MTV
represents a volumetric measurement of tumor cells with high glycolytic
activity and was defined as the tumor volume segmented with 18F-FDG
uptake above a threshold SUV of 2.5. We measured the SUVmax and
MTV of the primary tumor (pSUVmax and pMTV) and metastatic
LN (nSUVmax and nMTV) on the pretreatment scan. We also
calculated total lesion glycolysis (TLG) as the product of MTV and
average SUV in both the primary tumor (pTLG) and metastatic LN
(nTLG). In multiple metastatic nodes, nSUVmax reflected the
highest SUV among metastatic nodes, whereas nMTV and nTLG
indicated the sum of all nodes.
If the target lesion was not visualized or could not be distinguished
from background, SUVmax and MTV values were set as zero. When
the target lesion was visible but the SUVmax was less than 2.5, the
MTV was set as a single voxel with a volume of 0.05 cm3.
Statistical Analyses
To estimate the predictive performance of 18F-FDG PET
parameters, for time-to- event data, we used time-dependent
receiver operating characteristic (ROC) curve [20–22]. 18F-FDG
PET parameters were stratified using optimal cutoff values based on
the highest Youden’s index from time-dependent ROC curves at 24
months [23]. Univariate and multivariate analyses of pretreatment
variables were conducted using a Cox proportional hazards regression
model to identify significant variables for disease-free survival
(DFS) and overall survival (OS). Statistical analyses were performed
using SAS version 9.3 (SAS Institute, Cary, NC) and R 2.13.2
(Vienna, Austria; http://www.R-project.org/). Time-dependent
ROC curves were determined using the “survival ROC” package
for R [21]. All tests were two-sided, and P values b .05 were considered
statistically significant.
Table 1. Univariate Analyses for Survival Analyses of Clinical and PET Variables for Oral Cancer
Patient Survival
Pretreatment Variables DFS OS
HR 95% CI P HR 95% CI P
Age (1-year increase) 1.002 0.975-1.030 .888 1.020 0.983-1.059 .283
Gender (M vs F) 1.094 0.484-2.474 .828 1.065 0.375-3.027 .905
Clinical T classification
T3-4 vs T1-2 3.907 1.835-8.320 b .001 2.969 1.097-8.035 .032
Clinical N classification
N1-2 vs N0 1.708 0.821-3.554 .152 3.391 1.194-9.629 .022
18F-FDG PET measurements †
pSUVmax 3.862 1.648-9.049 .002 2.861 1.008-8.123 .048
pMTV 2.477 1.151-5.329 .020 1.866 0.710-4.906 .206
pTLG 2.881 1.276-6.508 .011 2.161 0.833-5.602 .113
nSUVmax 2.872 1.307-6.314 .009 5.444 2.097-14.134 b .001
nMTV 3.071 1.397-6.752 .005 4.428 1.684-11.642 .003
nTLG 2.978 1.355-6.547 .007 4.902 1.597-15.045 .006
HR, hazard ratio; CI, confidence interval; p, primary tumor; n, metastatic node.
Analyses conducted using Cox proportional hazard model.
† PET values were dichotomized using the optimal cutoff values.
Table 2. Multivariate Analysis of Clinical and PET Variables for Oral Cancer Patient Survival
Pretreatment variables DFS OS
HR 95% CI P HR 95% CI P
SUVmax model
Clinical T (T3-4 vs T1-2) 2.457 1.081-5.581 .032 2.101 0.691-6.389 .191
Clinical N (N1-2 vs N0) 0.526 0.187-1.477 .223 1.476 0.378-5.757 .575
pSUVmax 2.414 0.897-6.500 .081 1.392 0.403-4.811 .601
nSUVmax 3.182 1.094-9.254 .034 3.621 1.085-12.088 .036
MTV model
Clinical T (T3-4 vs T1-2) 2.882 1.230-6.753 .015 2.905 0.943-8.954 .063
Clinical N (N1-2 vs N0) 0.627 0.240-1.639 .341 1.460 0.348-6.131 .605
pMTV 1.357 0.563-3.269 .496 0.740 0.240-2.279 .600
nMTV 3.529 1.256-9.914 .017 3.486 0.898-13.526 .071
TLG model
Clinical T (T3-4 vs T1-2) 2.782 1.226-6.309 .014 3.065 0.752-12.491 .118
Clinical N (N1-2 vs N0) 0.615 0.233-1.621 .325 1.270 0.311-5.182 .739
pTLG 1.643 0.664-4.064 .282 0.696 0.173-2.795 .609
nTLG 3.358 1.180-9556 .023 4.122 0.872-19.483 .074
Analyses conducted using Cox proportional hazard model; p, primary tumor; n, metastatic node.
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LN Tumors
All animal experiment protocols were approved by the Institutional
Committee for Laboratory Animal Research. First, we tested which
tumors in primary sites versus in LNs spread more frequently to
distant organs. The SCCVII cells we used were cutaneous, moderately
differentiated, murine squamous cell carcinomas, syngeneic to C3H
mice, which had originally been isolated and cultured by Dr Herman
D. Suit (Harvard Medical School, Radiation Oncology).
To compare the occurrence of lung metastasis between primary and
LN tumors, we directly injected SCCVII tumor cells into the parotid/
upper cervical LN of C3H/HeJ mice (female, 6 weeks) using a
Hamilton syringe (1-5 × 104 cells in 1 μl;N = 13). Then, we compared
the occurrence of lung metastasis in these animals with that in animals
with ear tumors (N = 14).When the animals started losing body weight
(N10%), they were sacrificed and the tumors were collected. The tumor
volumes at the end point did not differ between the two groups (ear
tumor: 288 ± 42mm3, LN tumor: 312 ± 40mm3), and the time period
until the possible occurrence of lungmetastasis (loss of bodyweight) was
7 weeks (median) with a range of 5 to 12 weeks. For the control group
(N = 8), we removed the LN immediately after tumor cell injection to
exclude any possible effects of tumor cell leakage or direct systemic
dissemination due to the injection procedure.
Evaluation of SystemicMetastasis in Animals with Both Primary
and LN Tumors
Next, we created a clinically relevant animal model, in which each
animal had both primary and LN tumors. To differentiate between
these two tumors in the same mouse, we generated tumor cells
expressing either green fluorescence (SCCVII-GFP) or dual colors
(SCCVII-dsRed/GFP) and injected the tumor cells into the ear (5 × 105
cells in 100 μl) and the draining LN (1-5 × 104 cells in 1 μl)
simultaneously. When mice started losing body weight (N10%), they
were sacrificed and the tumors were collected. The tumors were
evaluated using fluorescentmicroscopy to determine the color expressed
within each metastatic tumor. We considered that the color of the
metastatic tumors identified the source tumor from which it originated
(ear or LN tumor). The “unitmetastasis potential” of the primary or LN
tumor was calculated as the tumor volume and number of lung
metastases divided by the original tumor volume. To exclude any
difference of metastatic potential between SCCVII-GFP andSCCVII-dsRed/GFP cells, we conducted two sets of experiments in
which the injection of the different colored tumor cells was switched
between the ear and LN (N = 11 and 8).
Results
PET Measurements of Metastatic LNs Have a Higher
Diagnostic Performance to Discriminate Survival Status
18F-FDG PET/CT correctly diagnosed 37 of 52 patients (71.2%)
with clinical neck metastases and 58 of 65 (89.2%) subjects without
neck metastases based on surgical pathology. These findings were
consistent with the previous study reporting that PET imaging does not
have high diagnostic performance to detect occult nodal metastases
[24].
To determine the best cutoff values for discriminating survival
status, we calculated Youden’s index (= sensitivity + specificity − 1)
(Table S2). We found a significantly better discrimination of DFS
status using nSUVmax than using pSUVmax (P = .045), suggesting that
nodal 18F-FDG PET measurements are better predictors of DFS
compared to the primary tumor. Similarly, we set the following cutoff
values for the best discrimination of OS status at 24 months. The area
under the curve from the time-dependent ROC curve analysis at 24
months was approximately 0.60 to 0.81, and there was no significant
difference in the discriminative power between primary tumor and
metastatic nodal 18F- FDG PET measurements in terms of OS.
PET Values of Metastatic LN Correlate with Prognosis Better
than Primary Tumor PET Values in Oral Cancer
We conducted survival analyses using clinical variables and
18F-FDG PET values to identify prognostic factors that significantly
affect survival. Because we were concerned with the clinical
decision-making and prognosis before any treatment initiation, we
included only the clinical variables as possible prognostic factors,
along with PET values. Univariate analysis indicated that clinical T
classification and all 18F-FDG PET values were significant prognostic
factors for DFS and that clinical T and N classifications, pSUVmax,
nSUVmax, nMTV, and nTLG were significant for OS (Table 1).
In the multivariate analyses, we excluded the variables that did not
reach statistical significance in univariate survival analyses (age and
gender) and included clinical T and N classifications and 18F-FDG
PET values. We rendered three separate multivariate models based on
Figure 1. Survival plots according to primary tumor and metastatic node18F-FDG PET values. (A) Representative cases: This patient had
T2 tongue cancer but no LNM (upper), whereas the other patient had small T1 tongue cancer with an ipsilateral LNM (lower). We
measured 18F-FDG PET values of primary tumor and LNM, separately using automatic volume calculation software with a threshold SUV
of 2.5. (B) Curves were estimated by the Cox proportional hazard model for multivariate analyses. DFS and OS were presented according
to the dichotomized pSUVmax and nSUVmax values, and these curves represented the relative survivals of two groups with other possible
factors adjusted. p, primary tumor; n, metastatic node.
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18F-FDG PET values (MTV and TLG),
because significant multi-collinearity existed among the 18F-FDG PET
measurements (variation inflation factor N 10). Regarding DFS, the
three multivariate models indicated that clinical T classification and
metastatic LN 18F-FDG PET values (nSUVmax, nMTV, and nTLG)
were significant risk factors (Table 2). In OS analyses, only the
metastatic LN nSUVmax showed statistical significance (Figure 1).
In addition, we found 15 distant metastases in our series during
follow-up: 1 in pN0, 3 in pN1 and 11 in pN2 (pN0 vs pN1-2, P b
.001). There were 12 distant metastasis in high nSUVmax (≥2.7) and 3
in low nSUVmax (b2.7; P = .008).LN Tumors Show a Higher Frequency of Lung Metastasis than
Primary Tumors in In Vivo Animal Models
LN tumors were formed by direct injection of tumor cells into the
LN, which solely reflected tumor growth of the same cancer cells in
different microenvironments. Tumors in the LN caused significantly
more and larger lung metastases than did primary ear tumors in tumor
volume–matched comparison (Figure 2).
One of eight animals in the control group (mice that underwent
immediate removal of the LN after tumor cell injection) showed lung
metastases, and three of eight mice had tumor formation in the
surrounding LN, suggesting that tumor cell leakages occurred during
Figure 2. Comparison of systemic metastasis from primary tumors and LN tumors. For LN tumor induction, tumor cells (SCCVII, 1-5 × 104
cells in 1 μl) were directly injected into the parotid/upper cervical LN of C3H/HeJ animals using a Hamilton syringe (N = 13). Ear tumors
were induced by injecting tumor cells (5 × 105 cells in 100 μl) into the ear (N = 14). When the animals started to lose body weights
(N10%), they were sacrificed and the occurrence of lung metastasis was compared between two groups. In the control group, we
removed the LN immediately after tumor cell injection into the LN (N = 8).
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number of lung metastases from tumors implanted directly in the LN,
compared to those from primary ear tumors, may come from
technical factors as well as differential tumor microenvironments
(soil). Considering the magnitude of lung metastasis, the tumors
established in the LN had a relatively high tendency of more lung
metastasis compared with those in the primary site (ear).
LN Tumors Have Higher Systemic Metastatic Capabilities
than Primary Tumors
Next, we evaluated the relative contribution of primary and LN tumors
to systemicmetastasis in an animalmodel having both tumors of different
colors simultaneously, similar to what a locally advanced HNC patient
might have. We calculated the original tumor volumes of ear and LN
tumors as well as the total volume or numbers of lung metastasis nodules.
After the tumor volume and number of lung nodules were divided by the
original color-matched tumor volume (defined as the unit metastasis
potentials), the calculated LN tumor values were found to be significantly
greater than the primary tumor values (Figure 3). The differencewas large,
even considering tumor cell leakage during the LN injection procedure.
Thus, these results suggest that a greater degree of systemic metastasis
occurred from established LN tumors compared to primary tumors.
Discussion
LNM in many solid cancers including HNC is a well-known and
clinically accepted prognostic factor [1,2]. However, the significance of
LNM has been debated for decades [3]. Here, we demonstrated that
there is more systemic spread from established LN tumors than from
primary tumors in preclinical animal models. In addition, in oral cancer
patients, we found that metabolic measurements of regional metastatic
LN correlated with patient DFS better than those of primary tumors.Thus, our data support the significance of LNM inHNC, which can be
the potential major source of further systemic metastasis [3].
This report is the first to provide direct clinical and experimental
evidence of LNM as a source of further cancer spread. Despite LNM
being as a strong prognostic factor for recurrence and survival, few
previous investigations regarding the significance of metastatic LNs have
been performed. Clinically, it is difficult to determine the tumor origin
from which systemic metastasis is derived. To overcome this limitation
and validate clinical findings of nodal metabolic significance, we
conducted two in vivo animal studies to evaluate the relative impact of
primary versus LN tumors on systemic metastasis. We confirmed higher
metastatic potential in establishedLN tumors, which is in accordancewith
the clinical findings. Tumor cells growing within the LN microenviron-
ment, compared with the same tumor cells growing in its primary site,
showed a higher frequency of lung metastasis, suggesting a role of the
unique LN microenvironment in the formation of systemic metastasis.
Still, the OS of HNC patients has not significantly improved
despite improved loco-regional control [25–28]. On the basis of our
data that proved a high risk of systemic metastasis from LNM in
HNC, it suggests some therapeutic implications to improve the OS in
HNC patients. Adjuvant systemic treatments that prevent the clinical
and fatal systemic diseases from circulating tumor cells [29,30] or
distant micro-metastasis [7] could be incorporated into the multi-
modality treatment protocols particularly in HNC patients with a
large burden of nodal diseases.
It is important to note the difference in tumor biology between the
primary site and LNs.We found that the metastatic capability of tumor
cells depended on the tumor microenvironment, because there was no
selection process of tumor cells in our study. Recent data also indicated
that the biology of the primary tumor differs from that of the metastatic
LNs [15–17], and importantly, tumor cells in differentmicroenvironments
Figure 3. Relative risk of systemic metastasis from primary and LN tumors. (A) To differentiate two tumors in the same mouse, we
simultaneously induced different colored tumors into the ear (5 × 105 cells in 100 μl) and the draining LN (1-5 × 104 cells in 1 μl):
SCCVII-GFP into the ear and SCCVII-dsRed/GFP into the LN and vice versa. When the animals started to lose body weight (N10%), animals
were sacrificed and tumors were evaluated using fluorescent microscopy to determine the color of each metastasis. (B) To exclude any
difference in metastatic potential between SCCVII-GFP and SCCVII-dsRed/GFP cells, we conducted two sets of experiments in which the
injection of the different colored tumor cells was switched between the ear and LN (N= 11 and 8). (C) We considered the color-matched
metastatic tumors as originating from the same color implanted tumor (ear or LN tumor). We calculated the unit metastasis potential of
the original tumors, defined as tumor volume or number of lung metastasis divided by the original tumor volume.
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tumor biology, drug response, and clinical trials do not evaluate the
setting of nodal metastasis. Thus, understanding tumor biology in each
metastatic site and evaluation of cancer based on the tumor and specific
metastatic microenvironment would help determine the optimal
treatment protocol and better predict prognosis.
However, our study had some limitations. Our in vivo models were
manipulated such that the possibility of tumor selection was completely
excluded, which may not reflect the real LNM from primary tumors.
Nevertheless, we could observe solely the differential impacts on tumor
dissemination of primary tumor sites and LNs without confounding of
tumor cell properties using our in vivomodels. So, we think our models
were best fit for studying the sole impact of tumor microenvironments
(soil), although they were very artificial. In addition, ear tumor models
probably did not reflect well the oral cavity cancer in human, where ear
tumors have less lymphatic vessels than oral cavity tumors. However, we
focused on each tumor growing in the primary sites or LNs, not on the
intervening lymphatics between them. If there were profuse lymphatics
in the primary sites, it is likely to have more lymphatic metastasis from
primary tumors.
In addition, we measured the rate and occurrence of lung
metastasis at only one time point. Thus, we cannot make any
conclusions about systemic spread over time from primary and LN
tumors. Moreover, the precise route leading into systemic circulation
was not determined in this study and requires further mechanisticinvestigation. However, one suggestion is the extracapsular spread of
LNM and extranodal blood vessels [31]. In clinical data, the volumetric
values of LNM appeared to be subject to a wide range of measurement
errors, perhaps due to the relatively small tumor volume of metastatic
node in the limitedN disease cases (N1). Another thing to note is that our
clinical study proved the significance of LNM in HNC patients, not
providing the direct evidence of systemic dissemination from LN tumors.
Thus, one should keep in mind that the formation of vital organ
metastasis may be a complex process contributed by intrinsic cancer cell
properties, tumor microenvironments, and their interactions. Neverthe-
less, we confirmed a strong correlation between nSUVmax and patient
survival. Finally, the study subjects were limited to oral cancer patients,
where surgical pathology was available. Thus, our results require future
validation in other types of HNC.
Tumor-Node-Metastasis (TNM) staging, which is currently the best
predictor of patient prognosis and the determinants of the treatment
method, simultaneously takes into account the primary tumor dimension
andLNMstatus.However, highT (T3-4), lowN (N0-1) stage and lowT
(T1-2), high N (N2-3) stage tumors are classified into the same TNM
staging category in HNC. In addition, a variety of non-surgical treatment
options leave pathologic T and N status unknown. According to our
current data, metabolic nodal imaging can be used as an additional tool
to provide pretreatment prognostic biomarkers and risk stratification,
along with the clinical TNM stage, because metabolic PET parameters
can reflect well the pathologic status (Table S3).
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In summary, the present study provided clinical and experimental data
regarding the significance of LNM in HNC and supported the
spectrum theory of tumor metastasis, where tumor cells gain more
metastatic capabilities as the tumor progresses to regional LNs inHNC.
Appendix A. . Supplementary data
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.tranon.2015.03.001.
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